logo
Products
Technologies
Applications
Services
Resources
Selection Guides
About
PE/iFluor® 594 Anti-human CD56 Antibody
My31
My31 is an anti-human monoclonal antibody that is specific for the CD56 antigen. CD56 (sometimes referred to as NCAM1, NKH1 or Leu-19) is a single-pass type I membrane protein that is found on the surface of cells like NK cells and T cells. CD56 is a component of key cellular pathways, namely, the interferon-gamma-mediated signaling pathway and regulation of semaphorin-plexin signaling pathway. Also, it has been closely linked to key biological processes like axon guidance, particularly commissural neuron axon guidance. From a research standpoint, it is of biological interest due to its association with key macromolecules/ligands such as NCAM-1. CD56 is a moderately popular antibody target, with over 18000 publications in the last decade. CD56 is frequently used in flow cytometry applications as a phenotypic marker for differentiation of cell types, particularly in the study of . This antibody was purified through affinity chromatography and conjugated to PE/iFluor® 594 (ex/em = 566/606 nm). It is compatible with the 561 nm laser and 615/20 nm bandpass filter (for example, as in the Agilent Technologies NovoCyte Quanteon).
product image
product image
CatalogSize
Price
Quantity
105621Y025 tests
Price
105621Y1100 tests
Price
105621Y2500 tests
Price
 
Antibody properties

Other namesLeu-19; NKH1; NCAM1
CloneMy31
Hostmouse
IsotypeMouse IgG1, κ
Reactivityhuman
Spectral properties

Absorbance (nm)566
Extinction coefficient (cm -1 M -1)
1960000
Excitation (nm)565
Emission (nm)606
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on October 4, 2025